Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co Ltd develops, produces, and sells pharmaceutical products, primarily focusing on traditional Chinese medicine and related formulations.
Business. Tianjin Chase Sun Pharmaceutical Co Ltd (300026.SZ) is a pharmaceutical company headquartered in Tianjin, China, operating within the Healthcare sector. The firm is primarily engaged in the research, development, and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange under the ticker symbol 300026.SZ. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Tianjin Chase Sun Pharmaceutical Co Ltd (300026.SZ) is a pharmaceutical company headquartered in Tianjin, China, operating within the Healthcare sector. The firm is primarily engaged in the research, development, and sale of pharmaceutical products. It is listed on the Shenzhen Stock Exchange under the ticker symbol 300026.SZ. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Tianjin Chase Sun Pharmaceutical Co Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.07, indicating minimal leverage. The company's liquidity position is characterized as medium, with a current ratio of 4.46, suggesting it can cover short-term obligations but may face constraints in highly volatile environments. Free cash flow of 117.85 million CNY supports operational flexibility, though capital expenditures of -130.25 million CNY suggest a reduction in investment activity.
Profitability metrics reveal a weak return on equity of 0.22% and a return on assets of 0.18%, both significantly below the industry median for pharmaceutical firms. Operating income of 102.87 million CNY and a net income of 18.50 million CNY indicate a narrow margin profile, with gross profit of 2.76 billion CNY representing 55.9% of revenue. These figures suggest the company is under pressure to improve cost efficiency and pricing power.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional demand fluctuations and regulatory changes. No material revenue is attributed to international markets, and the company does not report segment-specific performance metrics.
Growth trajectory appears muted, with no disclosed revenue growth rates or forward-looking guidance. Historical revenue of 4.94 billion CNY reflects a stable but non-expanding business model. The absence of disclosed R&D investment percentages or new product pipelines suggests limited innovation-driven growth.
Risk factors include a liquidity risk arising from negative net cash after subtracting total debt. The company's dilution risk is assessed as low, with no recent share issuance or ATM/shelf registration activity reported. No material risk factors are disclosed in 10-K filings or recent transcripts.
Recent events include no material earnings calls, regulatory filings, or press releases within the last 90 days. The company has not issued new guidance or disclosed material changes in business strategy. No significant legal or regulatory actions are reported in the latest filings.
- Tianjin Chase Sun Pharmaceutical Co Ltd operates with a low debt-to-equity ratio but faces liquidity constraints due to negative net cash after debt.
- The company's profitability metrics are below industry medians, indicating weak returns on equity and assets.
- Revenue is concentrated in a single segment with no geographic diversification, increasing exposure to regional risks.
- Growth appears to be driven by operational stability rather than innovation or expansion.
- Dilution risk is low, but liquidity risk remains a concern due to negative net cash.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Tianjin Chase Sun Pharmaceutical Co Ltd Market data — financials · 2026-05-26
- Tianjin Chase Sun Pharmaceutical Co Ltd Market data — ESG · 2026-05-26